Celebrity Inventors
Comic actor Danny Kaye received patent D166,807 for the co-design of "Blowout Toy or the Like". It's similar to one of those toys that unravels when you blow into at a birthday party except Kaye's has three blowouts going in different directions, not just one.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8093384 | Processes for the preparation of alfuzosin The invention relates to processes for the preparation of alfuzosin or pharmaceutically acceptable salts thereof in high purity. More particularly, it relates to the preparation of pure crystalline alfuzosin base. The invention also relates to pharmaceutical composi... | 01/10/2012 |
| 7262200 | Indazolinone compositions useful as kinase inhibitors The present invention provides compounds of formula I: These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK... | 08/28/2007 |
| 7238698 | Substituted quinazoline compounds useful as p38 kinase inhibitors Compounds having the formula (I), are useful as p38 kinase inhibitors, wherein R4 and R5 are hydrogen, halogen, cyano, haloalkyl, or haloalkoxy, but are not both hydrogen; R6 and ... | 07/03/2007 |
| 7211697 | Method for producing specific crystalline modifications of polmorphous substances The present invention pertains to a process for the production of a specific crystal modification of a polymorphic, organic substance by precipitation of the specific crystal modification from the aqueous solution of the salt of the polymorphic substances using ordi... | 05/01/2007 |
| 7205309 | Quinazoline derivatives Compounds of formula I as well as pharmaceutically acceptable salts and esters thereof, wherein R1, R2, R3 and A have the significance given in the specification are provided. The... | 04/17/2007 |
| 7176312 | Kinase inhibitor scaffolds and methods for their preparation General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls has been demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, bor... | 02/13/2007 |
| 7060825 | Process for synthesizing 6-quinazolinyl-ethyl-benzoyl and related antifolates The invention claimed herein relates to an improvement in a process for synthesizing a compound of formula Ib: wherein R1 and R2 are each individually amino or N-alkyl substituted amino; hydroxy; alkoxy; keto;... | 06/13/2006 |
| 6930113 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer... | 08/16/2005 |
| 6911446 | Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the inv... | 06/28/2005 |
| 6806274 | Quinazoline derivatives The invention concerns quinazoline derivatives of Formula (I) wherein Q1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q3—X1— wherein X | 10/19/2004 |
| 6800644 | Nitrogen-containing heterocyclic compounds and medicaments containing the compounds The present invention provides a novel nitrogen-containing heterocyclic compound useful as a phosphodiesterase-4 inhibitor, and a medicament comprising the same. Further, the present invention provides a nitrogen-containing heterocyclic compound represented by the f... | 10/05/2004 |
| 6794389 | Quinazoline derivatives and drugs There is provided an excellent novel analgesic having an analgesic effect which is effective widely against a pain including a chronic pain or an allodynia accompanied with herpes zoster by acting on a nociceptin receptor. The present invention relates to a c... | 09/21/2004 |
| 6733982 | Method for screening compounds for alpha1B adrenergic receptor antagonist and analgesic activity A method for identifying compounds that can be useful for producing analgesia is disclosed. In particular, the method involves providing preparation of a cell, that expresses an alpha1B adrenergic receptor, combining a test compound with the cell preparat... | 05/11/2004 |
| 6706705 | Quinazoline derivatives The present invention provides a new compound which shows slow and continuous blood pressure reducing action and is useful as an antihypertensive agent. The invention resides in a quinazoline derivative of the following formula (I) and its pharmaceutically ac... | 03/16/2004 |
| 6677339 | Phenylalanine derivatives Phenylalanine derivatives of formula (1) are described: ##STR1## in which: Ar1 is an aromatic or heteroaromatic group; L1 is a linker atom or group; R is a carboxylic acid or a derivative thereof; Ar2 is an optionall... | 01/13/2004 |
| 6649620 | Quinoline and quinazoline compounds useful in therapy Compounds of formula I, ##STR1## wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents an aryl group or a heteroaryl group, optionally substituted by C1-4 ... | 11/18/2003 |
| 6642242 | Quinoline and quinazoline compounds useful in therapy The invention provides compounds of formula (I), ##STR1## wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents H or C1-6 alkoxy optionally substituted by one or m... | 11/04/2003 |
| 6608200 | Process for the preparation of N-(2,3-Dihydrobenzo[1,4]dioxin-2-carbonyl)piperazine Described herein is an improved process for the preparation of N-(2,3-Dihydrobenzo[1,4]dioxin-2-carbonyl)piperazine which includes heating a reaction mixture ethyl of 2,3-dihydrobenzo[1,4]dioxin-2-carboxylate and piperazine. The reaction mixture is t... | 08/19/2003 |
| 6608055 | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition The invention relates to crystalline anhydrous (1,2ଲ,4ଲ,5,7ଲ)-7-[(hydroxydi-2-thienylacetyl) oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.022,4 ]nonane-bromide, processes for preparing it and its use for prepari... | 08/19/2003 |
| 6559153 | Quinazoline derivatives as alpha-1 adrenergic antagonists This invention relates to compounds which are generally alpha-1B adrenergic receptor antagonists and which are represented by Formula (I): ##STR1## wherein R', R", R1, R2, m, n, and A are as defined in the specification, or acceptabl... | 05/06/2003 |
| 6545003 | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g.... | 04/08/2003 |
| 6525195 | Method for obtaining polymorph a from doxazosine mesylate The invention discloses a process for the preparation of the polymorh A of doxazosin meylate, consisting essentially of reacting doxazosin base with methanesulfonic acid in a mixture of solvents containing an alcohol and a chlorinated solvent, subsequentl... | 02/25/2003 |
| 6500830 | Conversion of modification D to modification A of doxazosin mesylate A process for preparing doxazosin mesylate in modification A which comprises dissolving doxazosin with methanesulfonic acid in methanol or a mixture of an aprotic, polar organic solvent and methanol, removing any turbidity from the resulting solution, and... | 12/31/2002 |
| 6476033 | Medicaments containing doxazosin mesylate of crystalline modification D Drugs comprising modification D of doxazosin mesylate are described. They are suitable for treating high blood pressure.... | 11/05/2002 |
| 6458798 | Bicyclic pyrimidine compounds and therapeutic use thereof A pyrimidine derivative of the formula (1) or a salt thereof; ##STR1## has an inhibitory activity of production of Th2 type cytokines such as IL-4, IL-5, etc., and is useful as an therapeutic agent for allergic diseases, autoimmune diseases such as system... | 10/01/2002 |
| 6417194 | Quinolines and quinazolines useful in therapy Compounds of formula I, ##STR1## wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 and R3 independently represent H or C1-6 alkoxy (which is optionally substit... | 07/09/2002 |
| 6399775 | Methods for the preparation of polymorphs of doxazosin mesylate Form D of doxazosin mesylate and a process for preparing Form D of doxazosin mesylate is described. The process is (a) dissolving doxazosin base and methane sulfonic acid in an alcohol having 1 to 8 carbon atoms; (b) precipitating Form D of doxazosin mesy... | 06/04/2002 |
| 6352989 | Nitrogenous heterocyclic derivatives and medicine thereof The present invention provides a novel nitrogen-containing heterocyclic compound useful as a phosphodiesterase-4 inhibitor, and a medicament comprising the same. Further, the present invention provides a nitrogen-containing heterocyclic compound represent... | 03/05/2002 |
| 6348463 | Phenylalanine derivatives Phenylalanine derivatives of formula (1) are described: ##STR1## in which: Ar1 is an aromatic or heteroaromatic group; L1 is a linker atom or group; R is a carboxylic acid or a derivative thereof; Ar2 is an optionally substituted ar... | 02/19/2002 |
| 6339089 | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same A pyrimidine nucleus-containing compound represented by the formula (I): ##STR1## wherein ring A represents the ring of the formula (a): ##STR2## in which R1 is a nitro group, an amino group, a substituted amino group or a halogen atom, or the ... | 01/15/2002 |
| 6313294 | Process for preparing amides The present invention provides a process for preparing an amide, which comprises reacting an amine with an ester in a molten form in the absence of a solvent.... | 11/06/2001 |
| 6258952 | Thermally stable trimetrexates and processes for producing the same The present invention provides for thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. A crystalline 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline monohydrate, or tri... | 07/10/2001 |
| 6258821 | Compositions comprising trimetrexate and methods of their synthesis and use This invention is directed to the novel composition of matter trimetrexate ascorbate, to compositions comprising trimetrexate ascorbate, and to compositions comprising trimetrexate and ascorbic acid. These compositions are useful in the treatment of disea... | 07/10/2001 |
| 6248888 | Process for the preparation of terazosin hydrochloride dihydrate A process for the preparation of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate, and the product produced thereby, comprising reacting by heating 2-chloro-4-amino-6,7-dimethoxyquinazoline and 1-(2-te... | 06/19/2001 |
| 6204267 | Methods of modulating serine/thereonine protein kinase function with quinazoline-based compounds The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with quinazoline-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In additi... | 03/20/2001 |
| 6140334 | Polymorphic form of doxazosin mesylate (form III) A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 8.49°, 11.72°, 16.03°, 18.29°... | 10/31/2000 |
| 6133269 | Polymorphic form of doxazosin mesylate (form II) A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 10.68°, 14.45°, 17.37°, 23.45Â... | 10/17/2000 |
| 6130218 | Polymorphic form of doxazosin mesylate (Form I) A new crystalline and anhydrous form of doxazosin mesylate is described. The new form is crystalline and anhydrous and is characterized in its X-ray spectrum by the following reflex positions of high and medium intensity: 15.40°, 16.85°, 18.06°, 24.15Â... | 10/10/2000 |
| 6080860 | Methods of making ureas and guanidines including, terazosin, prazosin, doxazosin, tiodazosin, trimazosin, quinazosin and bunazosin (exemplary of 2-substituted quinazoline compounds), and meobentine, and bethanidine and intermediates therefor Novel methods for the synthesis of substituted ureas and guanidines including Terazosin, Prazosin, Doxazosin, Tiodazosin, Trimazosin, Quinasin and Bunazosin (exemplary of 2-amino substituted Quinazolines), Meobentine and Bethanidine and novel intermediate... | 06/27/2000 |
| 6048864 | Quinolines and quinazolines useful in therapy Compounds of formula I, ##STR1## wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 and R3 independently represent H or C1-6 alkoxy (which is optionally su... | 04/11/2000 |
